Certificate of analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Tuftsin analogue |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form: TKPRPGP |
| Molecular formula | C33H57N11O9 | Calculated for the free peptide |
| Molecular weight | About 751.9 g/mol | Derived from the sequence |
| Appearance | White to off-white powder | Typical lyophilised form |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Operating a CH station was a manpower-intensive situation, with an operator in the transmitter hut, an operator and assistant in the receiver hut, and as many as six assistants in the receiver hut operating the plotters, calculators and telephone systems. In order to provide 24-hour service, multiple crews were needed, along with a number of service and support personnel. This was then multiplied by the reporting hierarchy, which required similar numbers of WAAFs at each level of the Dowding system hierarchy. Plotting the angle of the target was a simple process of taking the gonio reading and setting a rotating straightedge to that value. The problem was determining where along that straightedge the target lay; the radar measured the slant range straight-line distance to the target, not the distance over the ground. That distance was affected by the target's altitude, which had to be determined by taking the somewhat time-consuming altitude measurements. Additionally, that altitude was affected by the range, due to the curvature of the Earth, as well as any imperfections in the local environment, which caused the lobes to have different measurements depending on the target angle. As no small part of the manpower required was dedicated to calculation and plotting, a great reduction could be made by using as much automation as possible. This started with the use of various mechanical aids; these were eventually replaced by the fruit machine, an electromechanical analogue computer of some complexity. It replicated all of these devices and tables in electrical form.
One should expect that, within a few thousand years of its entering the stage of industrial development, any intelligent species should be found occupying an artificial biosphere which surrounds its parent star. Dyson conceived that such structures would be clouds of asteroid-sized space habitats, though science fiction writers have preferred a solid structure: either way, such an artifact is often called a Dyson sphere, although Dyson used the term "shell". Dyson said that he used the term "artificial biosphere" in the article to mean a habitat, not a shape. The general concept of such an energy-transferring shell had been created decades earlier by science fiction writer Olaf Stapledon in his 1937 novel Star Maker, a source which Dyson credited publicly. Freeman Dyson was interviewed by Robert Wright in 2003 and the Dyson Sphere topic was broached. In response he stated that the paper he wrote on this concept was intended to be a joke and had nothing to do with work. He added that it amused him that he had become famous only for the things he didn't think were serious.
== Efficacy == IPT has not been proven to work. Lab research indicates that there is not even a theoretical possibility of it being an effective treatment for most cancers. Research over the decades has proved that most cancers grow when exposed to more insulin. One study of men with prostate cancer showed that survival was significantly shorter (11 months for men who received IPT vs 18.9 months for men on standard treatment). A second small trial showed that women with metastatic breast cancer were less likely to see short-term disease progression if they received IPT with low-dose methotrexate than if they received either insulin alone or low-dose methotrexate alone. (This study did not compare IPT against any of the proven multi-drug chemotherapy regimens.)
Variations in both the BDNF and BDNF-AS genes are important factors to consider, given their potential to alter BDNF function and contribute to multiple human phenotypes influencing disease susceptibility and treatment outcomes.
Sources: en.wikipedia.org
Ene-reductase (ER, ERED) is an enzyme able to catalyze the stereoselective reduction of carbon-carbon double bonds (C=C) that are activated by electron withdrawing groups (EWG), like aldehydes, ketones and esters. The catalytic cycle is dependent from the cofactor nicotinamide adenine dinucleotide phosphate (NADPH). Unlike traditional stereoselective chemical hydrogenation, that often uses noble metals and harsh conditions, ERs can operate under mild and aqueous conditions and their stereoselectivity depends on the specific enzyme.
==== Conventional recycle processes ==== In early "straight-through" urea plants, reactant recovery (the first step in recycling) was done by letting down the system pressure to atmospheric to let the carbamate decompose back to ammonia and carbon dioxide. Originally, because it was not economic to recompress the ammonia and carbon dioxide for recycle, the ammonia at least would be used for the manufacture of other products such as ammonium nitrate or ammonium sulfate, and the carbon dioxide was usually wasted. Later process schemes made recycling unused ammonia and carbon dioxide practical. This was accomplished by the "total recycle process", developed in the 1940s to 1960s and now called the conventional recycle process. It proceeds by depressurizing the reaction solution in stages (first to 1.8–2.5 MPa (260–360 psi) and then to 0.2–0.5 MPa (29–73 psi)) and passing it at each stage through a steam-heated carbamate decomposer, then recombining the resulting carbon dioxide and ammonia in a falling-film carbamate condenser and pumping the carbamate solution back into the urea reaction vessel.
First MD simulation of a simplified biological folding process was published in 1975. Its simulation published in Nature paved the way for the vast area of modern computational protein-folding. First MD simulation of a biological process was published in 1976. Its simulation published in Nature paved the way for understanding protein motion as essential in function and not just accessory. MD is the standard method to treat collision cascades in the heat spike regime, i.e., the effects that energetic neutron and ion irradiation have on solids and solid surfaces. The following biophysical examples illustrate notable efforts to produce simulations of a systems of very large size (a complete virus) or very long simulation times (up to 1.112 milliseconds):
Sources: en.wikipedia.org
=== Other drugs === Various other types of drugs have also been found to produce hypnotic-type effects in scientific research. Examples include histamine H3 receptor agonists like α-methylhistamine, BP 2.94, GT-2203 (VUF-5296), and SCH-50971, adenosine A1 and A2A receptor agonists like adenosine and YZG-331, and dopamine D1 receptor receptor antagonists like NNC 01-0687 (ADX-10061, CEE-03-310, NNC-687). Pellotine, a tetrahydroisoquinoline alkaloid found in Lophophora cacti species such as Lophophora diffusa (false peyote) and Lophophora williamsii (peyote), is a hypnotic that was previously marketed in Europe in the 1890s but was abandoned once cheaper barbiturates were introduced the next decade. It has been identified as a selective and potent serotonin 5-HT6 receptor weak partial agonist, serotonin 5-HT7 receptor inverse agonist, and serotonin 5-HT1D receptor ligand, with one or more of these actions possibly involved in its sedative and hypnotic effects. Tributyrin, a triglyceride (fat) and precursor or prodrug of butyric acid (butyrate), a short-chain fatty acid and major product of beneficial gut bacteria, has been found to increase slow wave sleep (SWS) and deep sleep in rodents and humans.
=== Sequence-controlled chemical polymerizations === Other than biological polymerization methods, scientists have also developed numerous chemical synthetic methods for sequence-controlled polymers. Compared with biological polymerization, chemical polymerization can provide better diversity but most of the chemical methods cannot offer the efficiency and specificity of biological methods.
== Medical uses == Etoperidone was used or was intended for use as an antidepressant in the treatment of depression. Etoperidone might be useful as a hallucinogen antidote or "trip killer" in blocking the effects of serotonergic psychedelics like psilocybin and lysergic acid diethylamide (LSD).
Sources: en.wikipedia.org
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.
Selank is a synthetic analogue built on the tuftsin tetrapeptide Thr-Lys-Pro-Arg. Extra proline residues were added to the C-terminus during design work. That modification is intended to make the peptide less vulnerable to rapid enzymatic degradation.
Transliteration from Russian produces variant spellings such as Selanc. Many suppliers avoid the trade-style name entirely and list the peptide sequence. Comparing sequences rather than names is the reliable way to confirm two entries describe the same molecule.
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.